| 3464 | Humans |
| 2025 | Animals |
| 978 | SARS Virus (genetics) |
| 935 | Severe Acute Respiratory Syndrome (virology) |
| 704 | SARS Virus (immunology) |
| 694 | Female |
| 654 | Severe Acute Respiratory Syndrome (epidemiology) |
| 597 | Male |
| 583 | Mice |
| 578 | Severe acute respiratory syndrome |
| 567 | Spike Glycoprotein, Coronavirus |
| 566 | SARS Virus (isolation & purification) |
| 564 | Coronavirus |
| 525 | Molecular Sequence Data |
| 501 | Cell Line |
| 466 | Chlorocebus aethiops |
| 466 | Amino Acid Sequence |
| 461 | Adult |
| 452 | Severe Acute Respiratory Syndrome (prevention & control) |
| 428 | Severe Acute Respiratory Syndrome (diagnosis) |
| 424 | SARS Virus (physiology) |
| 419 | Severe Acute Respiratory Syndrome (immunology) |
| 402 | Disease Outbreaks |
| 387 | Vero Cells |
| 381 | SARS Virus (pathogenicity) |
| 372 | Middle Aged |
| 362 | SARS Virus (metabolism) |
| 347 | Severe Acute Respiratory Syndrome (transmission) |
| 340 | Viral Envelope Proteins (genetics) |
| 330 | Antiviral Agents (pharmacology) |
| 312 | Coronavirus Infections (virology) |
| 303 | Models, Molecular |
| 297 | Antibodies, Viral (blood) |
| 289 | Membrane Glycoproteins (genetics) |
| 276 | SARS Virus |
| 274 | SARS Virus (drug effects) |
| 265 | Viral Envelope Proteins (metabolism) |
| 265 | Coronavirus Infections (epidemiology) |
| 251 | Genome, Viral |
| 244 | Viral Envelope Proteins (immunology) |
| 242 | Protein Binding |
| 242 | Phylogeny |
| 238 | Base Sequence |
| 235 | Aged |
| 227 | Human |
| 224 | Viral Envelope Proteins (chemistry) |
| 224 | Membrane Glycoproteins (immunology) |
| 221 | SARS Virus (enzymology) |
| 221 | SARS Virus (chemistry) |
| 220 | Pandemics |
| 220 | Mice, Inbred BALB C |
| 219 | Virus Replication |
| 219 | Viral Proteins (metabolism) |
| 218 | Protein Structure, Tertiary |
| 217 | China (epidemiology) |
| 215 | Membrane Glycoproteins (metabolism) |
| 211 | Reverse Transcriptase Polymerase Chain Reaction |
| 209 | Microbiology |
| 205 | Severe acute respiratory syndrome virus |
| 202 | Virology |
| 198 | Viral Proteins (chemistry) |
| 197 | Viral Proteins (genetics) |
| 196 | Severe Acute Respiratory Syndrome (drug therapy) |
| 193 | Betacoronavirus |
| 192 | RNA, Viral (genetics) |
| 189 | Membrane Glycoproteins (chemistry) |
| 188 | Viral Vaccines (immunology) |
| 187 | Structure-Activity Relationship |
| 185 | Coronavirus (genetics) |
| 184 | Adolescent |
| 183 | China |
| 170 | Pneumonia, Viral (epidemiology) |
| 169 | Coronavirus Infections (transmission) |
| 169 | Antibodies, Viral (immunology) |
| 164 | Severe Acute Respiratory Syndrome (pathology) |
| 163 | Chiroptera (virology) |
| 163 | Antiviral Agents (chemistry) |
| 162 | Enzyme-Linked Immunosorbent Assay |
| 161 | Mutation |
| 161 | Disease Models, Animal |
| 160 | Disease Outbreaks (prevention & control) |
| 159 | Sensitivity and Specificity |
| 156 | Binding Sites |
| 156 | Antiviral Agents (therapeutic use) |
| 155 | Time Factors |
| 153 | Protein Conformation |
| 153 | Neutralization Tests |
| 153 | Antiviral |
| 150 | Communicable Diseases, Emerging (epidemiology) |
| 150 | Child |
| 149 | Global Health |
| 149 | Coronavirus Infections (diagnosis) |
| 145 | Coronavirus (isolation & purification) |
| 139 | Protein |
| 135 | Lung (virology) |
| 130 | Virus Replication (drug effects) |
| 129 | Influenza, Human (epidemiology) |
| 127 | Lung (pathology) |
| 126 | Drug Design |
| 123 | Nucleocapsid Proteins (genetics) |
| 121 | Nucleocapsid Proteins (immunology) |
| 120 | Crystallography, X-Ray |
| 118 | Sequence Alignment |
| 118 | Receptors, Virus (metabolism) |
| 116 | Severe Acute Respiratory Syndrome (therapy) |
| 112 | Coronavirus Infections (prevention & control) |
| 111 | SARS Virus (classification) |
| 111 | Pneumonia, Viral (transmission) |
| 111 | Cells, Cultured |
| 109 | Travel |
| 109 | Communicable Diseases, Emerging (virology) |
| 108 | Immunoglobulin G (blood) |
| 108 | Hong Kong (epidemiology) |
| 108 | Coronavirus (classification) |
| 106 | Peptidyl-Dipeptidase A (metabolism) |
| 105 | Risk Factors |
| 101 | Aged, 80 and over |
| 100 | Cysteine Endopeptidases (chemistry) |
| 99 | Viral Proteins (antagonists & inhibitors) |
| 98 | Viral Nonstructural Proteins (metabolism) |
| 98 | Sequence Analysis, DNA |
| 98 | Cricetinae |
| 97 | RNA, Viral (analysis) |
| 97 | Communicable Diseases, Emerging (prevention & control) |
| 95 | Pneumonia, Viral (virology) |
| 95 | Pneumonia, Viral (diagnosis) |
| 95 | Cloning, Molecular |
| 95 | Child, Preschool |
| 94 | Molecular Structure |
| 94 | Coronavirus Infections (drug therapy) |
| 93 | Evolution, Molecular |
| 93 | Blotting, Western |
| 92 | Infection |
| 91 | Sequence Homology, Amino Acid |
| 91 | Cysteine Endopeptidases (metabolism) |
| 90 | Virus Internalization |
| 90 | Severe Acute Respiratory Syndrome (genetics) |
| 89 | World Health Organization |
| 89 | Viral Nonstructural Proteins (genetics) |
| 87 | Severe Acute Respiratory Syndrome (metabolism) |
| 87 | Recombinant Proteins (immunology) |
| 87 | Nucleocapsid Proteins (metabolism) |
| 86 | Kinetics |
| 85 | Coronavirus (physiology) |
| 85 | Antiviral Agents (chemical synthesis) |
| 84 | Gene Expression |
| 84 | Antibodies, Monoclonal (immunology) |
| 83 | Infant |
| 83 | In vitro |
| 83 | Coronavirus Infections (immunology) |
| 82 | SARS Virus (growth & development) |
| 82 | Recombinant Proteins (genetics) |
| 81 | Severe Acute Respiratory Syndrome (physiopathology) |
| 80 | Structure activity relation |
| 80 | Acute |
| 79 | Viral Vaccines (administration & dosage) |
| 79 | Protein Structure, Secondary |
| 79 | Models, Biological |
| 79 | Host-Pathogen Interactions |
| 78 | Retrospective Studies |
| 78 | Influenza, Human (virology) |
| 76 | Hong Kong |
| 75 | Zoonoses (virology) |
| 75 | Severe Acute Respiratory Syndrome (mortality) |
| 75 | Public Health |
| 75 | Protease Inhibitors (pharmacology) |
| 75 | Polymerase Chain Reaction |
| 75 | Murine hepatitis virus (genetics) |
| 74 | Virus |
| 74 | Dose-Response Relationship, Drug |
| 73 | Transfection |
| 73 | Respiratory Tract Infections (virology) |
| 73 | RNA, Viral (metabolism) |
| 73 | Influenza, Human (prevention & control) |
| 72 | Young Adult |
| 72 | Escherichia coli (genetics) |
| 72 | Coronavirus Infections (veterinary) |
| 72 | Betacoronavirus (genetics) |
| 71 | Viral Nonstructural Proteins (chemistry) |
| 71 | Recombinant Proteins (metabolism) |
| 71 | Nucleocapsid Proteins (chemistry) |
| 70 | Vaccination |
| 70 | Peptides (chemistry) |
| 70 | HeLa Cells |
| 70 | Coronavirus (pathogenicity) |
| 70 | Antigens, Viral (immunology) |
| 69 | Severe Acute Respiratory Syndrome (blood) |
| 69 | Open Reading Frames |
| 68 | Virulence |
| 68 | Pandemics (prevention & control) |
| 68 | Genetic Variation |
| 67 | Zoonoses |
| 67 | Epidemic |
| 67 | Communicable Diseases, Emerging (transmission) |
| 66 | Viral Matrix Proteins (genetics) |
| 66 | Computer Simulation |
| 65 | Viral Envelope Proteins (physiology) |
| 64 | Vaccine |
| 64 | Swine |
| 64 | Epidemiology |
| 63 | Species Specificity |
| 63 | Severe Acute Respiratory Syndrome (complications) |
| 63 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
| 63 | Pneumonia, Viral (prevention & control) |
| 63 | Mice, Inbred C57BL |
| 63 | Detection |
| 62 | Viral Load |
| 62 | Protease Inhibitors (chemistry) |
| 62 | Influenza, Human (transmission) |
| 62 | Feces (virology) |
| 61 | Membrane Glycoproteins (physiology) |
| 61 | Infection Control (methods) |
| 61 | Immunization |
| 61 | Genetic Vectors |
| 61 | Coronavirus (immunology) |
| 60 | Viral Matrix Proteins (metabolism) |
| 60 | Replication |
| 59 | Zoonoses (transmission) |
| 59 | Viral Vaccines |
| 59 | RNA Replicase (genetics) |
| 59 | Gene Expression Regulation, Viral |
| 58 | United States (epidemiology) |
| 58 | Recombination, Genetic |
| 58 | Immunity, Innate |
| 58 | DNA, Viral (genetics) |
| 57 | Viral Vaccines (genetics) |
| 57 | Risk Assessment |
| 57 | Murine hepatitis virus (physiology) |
| 57 | Coronavirus Infections |
| 57 | Coronavirus Infections (therapy) |
| 57 | Chemical synthesis |
| 56 | Rabbits |
| 56 | HEK293 Cells |
| 55 | Zoonoses (epidemiology) |
| 55 | United States |
| 55 | SARS |
| 55 | Reproducibility of Results |
| 55 | Lung (immunology) |
| 55 | Betacoronavirus (isolation & purification) |
| 54 | Influenza A Virus, H1N1 Subtype |
| 54 | Disease Reservoirs |
| 54 | Algorithms |
| 53 | Viral disease |
| 53 | RNA, Viral (chemistry) |
| 53 | Prevention |
| 53 | Pneumonia, Viral |
| 53 | Middle East Respiratory Syndrome Coronavirus (genetics) |
| 53 | Infection Control |
| 53 | HIV-1 (drug effects) |
| 53 | Computational Biology |
| 53 | Clinical Laboratory Techniques |
| 53 | Cell Line, Tumor |
| 53 | Apoptosis |
| 52 | Virus Diseases (virology) |
| 52 | Prognosis |
| 52 | Genes, Viral |
| 52 | Enzyme inhibitor |
| 52 | Dimerization |
| 52 | DNA Primers |
| 52 | Catalytic Domain |
| 51 | RNA, Viral (isolation & purification) |
| 51 | Mouse |
| 51 | Microbial Sensitivity Tests |
| 51 | Disease Reservoirs (virology) |
| 50 | Taiwan (epidemiology) |
| 50 | Diagnosis |
| 50 | Contact Tracing |
| 50 | Betacoronavirus (pathogenicity) |
| 49 | Substrate Specificity |
| 49 | Recombinant Proteins (chemistry) |
| 49 | Influenza |
| 49 | Amino Acid Substitution |
| 48 | Treatment |
| 48 | Spike Glycoprotein, Coronavirus (metabolism) |
| 48 | Severe Acute Respiratory Syndrome |
| 48 | Rats |
| 48 | Quarantine |
| 48 | Peptidyl-Dipeptidase A (genetics) |
| 48 | Diagnosis, Differential |
| 47 | Recombinant Fusion Proteins (genetics) |
| 47 | Mutagenesis, Site-Directed |
| 47 | Inhibitory Concentration 50 |
| 46 | Virus Diseases (epidemiology) |
| 46 | Pneumonia |
| 46 | Modeling |
| 46 | Epithelial Cells (virology) |
| 46 | Disease Outbreaks (statistics & numerical data) |
| 45 | RNA Replicase (metabolism) |
| 45 | Nucleocapsid |
| 45 | Flow Cytometry |
| 45 | Escherichia coli (metabolism) |
| 44 | Severity of Illness Index |
| 44 | Health Personnel |
| 44 | Communicable Disease Control (methods) |
| 43 | Middle East Respiratory Syndrome Coronavirus (physiology) |
| 43 | Incidence |
| 43 | Genotype |
| 43 | Cytokines (metabolism) |
| 43 | Cross Infection (prevention & control) |
| 43 | Coronavirus Infections (pathology) |
| 43 | Coronavirus (drug effects) |
| 43 | Cats |
| 43 | CD8-Positive T-Lymphocytes (immunology) |
| 42 | Vaccines, DNA (immunology) |
| 42 | Severe Acute Respiratory Syndrome (etiology) |
| 42 | Recombinant Fusion Proteins (metabolism) |
| 42 | RNA, Messenger (genetics) |
| 42 | Protein Multimerization |
| 42 | Population Surveillance |
| 42 | Polymerase Chain Reaction (methods) |
| 42 | Peptidyl-Dipeptidase A |
| 42 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
| 42 | Microscopy, Electron |
| 42 | Chiroptera |
| 41 | Virus Replication (physiology) |
| 41 | Virus Diseases (prevention & control) |
| 41 | Viral Proteins (immunology) |
| 41 | SARS Virus (ultrastructure) |
| 41 | Receptors, Virus (genetics) |
| 41 | RNA Replicase (chemistry) |
| 41 | Immunohistochemistry |
| 41 | Enzyme Inhibitors (pharmacology) |
| 41 | Antibodies, Viral (biosynthesis) |
| 40 | Spike Glycoprotein, Coronavirus (genetics) |
| 40 | Respiratory tract |
| 40 | Public health |
| 40 | Pneumonia, Viral (therapy) |
| 40 | Cross Infection (epidemiology) |
| 40 | Coronavirus Infections (complications) |
| 40 | Communicable Disease Control |
| 40 | Cluster Analysis |
| 39 | Peptide Hydrolases (metabolism) |
| 39 | Murine hepatitis virus (pathogenicity) |
| 39 | Membrane Fusion |
| 39 | Cysteine Endopeptidases (genetics) |
| 39 | Coronavirus (metabolism) |
| 39 | Communicable Diseases, Emerging (diagnosis) |
| 39 | Amino Acid Motifs |
| 38 | Transcription, Genetic |
| 38 | Spike Glycoprotein, Coronavirus (chemistry) |
| 38 | Sequence Deletion |
| 38 | RNA, Messenger (metabolism) |
| 38 | Prevalence |
| 38 | Gene Expression Profiling |
| 38 | Epitopes (immunology) |
| 38 | Epitope Mapping |
| 38 | Communicable Diseases, Emerging |
| 37 | Treatment Outcome |
| 37 | Singapore (epidemiology) |
| 37 | Peptide Library |
| 37 | Circular Dichroism |
| 37 | Antigens, Viral (genetics) |
| 37 | Antibody Specificity |
| 37 | Anti-HIV Agents (pharmacology) |
| 36 | Review |
| 36 | Respiratory Tract Infections (epidemiology) |
| 36 | Pregnancy |
| 36 | Pneumonia, Viral (drug therapy) |
| 36 | Peptidases |
| 36 | Molecular model |
| 36 | Molecular Docking Simulation |
| 36 | Middle East Respiratory Syndrome Coronavirus |
| 36 | Immunoglobulin M (blood) |
| 36 | Fluorescent Antibody Technique |
| 36 | Cross Reactions |
| 36 | Coronavirus Infections (metabolism) |
| 36 | Cell Fusion |
| 36 | Canada (epidemiology) |
| 36 | Animal |
| 35 | Virus Diseases (diagnosis) |
| 35 | Vaccines, Synthetic (immunology) |
| 35 | Survival Analysis |
| 35 | Protein Folding |
| 35 | Pneumonia, Viral (complications) |
| 35 | Patient Isolation |
| 35 | Murine hepatitis virus (metabolism) |
| 35 | Models, Statistical |
| 35 | Macaca mulatta |
| 35 | Gene Expression Regulation |
| 35 | Dogs |
| 35 | Cysteine Endopeptidases |
| 35 | Conserved Sequence |
| 35 | Cattle |
| 35 | Birds |
| 35 | Antibody |
| 34 | Virus Assembly |
| 34 | Recombinant Proteins (biosynthesis) |
| 34 | Infant, Newborn |
| 34 | Hospitalization |
| 34 | Emerging disease |
| 34 | Case-Control Studies |
| 33 | Viral Matrix Proteins (chemistry) |
| 33 | Viral Envelope Proteins (biosynthesis) |
| 33 | Temperature |
| 33 | T-Lymphocytes, Cytotoxic (immunology) |
| 33 | T-Lymphocytes (immunology) |
| 33 | Risk |
| 33 | Immunoglobulin G (immunology) |
| 33 | Identification |
| 33 | Hospital |
| 33 | Glycosylation |
| 33 | Electrophoresis, Polyacrylamide Gel |
| 32 | Virus Replication (genetics) |
| 32 | Signal Transduction |
| 32 | Seroepidemiologic Studies |
| 32 | Ribavirin (therapeutic use) |
| 32 | Reverse transcription polymerase chain reaction |
| 32 | Reverse Transcriptase Inhibitors (pharmacology) |
| 32 | Neutralizing antibody |
| 32 | Models, Genetic |
| 32 | Mice, Transgenic |
| 32 | Follow-Up Studies |
| 32 | Cytopathogenic Effect, Viral |
| 32 | Coronavirus (enzymology) |
| 32 | Chickens |
| 32 | Cell Membrane (metabolism) |
| 32 | COS Cells |
| 31 | Virus Diseases (transmission) |
| 31 | Software |
| 31 | Severe |
| 31 | Recombinant Proteins (isolation & purification) |
| 31 | RNA, Small Interfering (genetics) |
| 31 | Peptides |
| 31 | Method |
| 31 | Membrane Proteins (metabolism) |
| 31 | International Cooperation |
| 31 | Disease Transmission, Infectious |
| 31 | DNA, Viral (analysis) |
| 31 | Canada |
| 31 | Antibodies, Viral (analysis) |
| 30 | Taiwan |
| 30 | Real-Time Polymerase Chain Reaction |
| 30 | Radiography |
| 30 | Protein Structure, Quaternary |
| 30 | Protein Processing, Post-Translational |
| 30 | Plasmids |
| 30 | Nucleic Acid Conformation |
| 30 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
| 30 | Medicine |
| 30 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 30 | Immune response |
| 30 | Genome, Viral (genetics) |
| 30 | Fluorescent Antibody Technique, Indirect |
| 30 | Enzyme-Linked Immunosorbent Assay (methods) |
| 29 | severe acute respiratory syndrome |
| 29 | Viverridae (virology) |
| 29 | Viruses (isolation & purification) |
| 29 | Nasopharynx (virology) |
| 29 | Microscopy, Fluorescence |
| 29 | Influenza, Human (diagnosis) |
| 29 | Hydrogen-Ion Concentration |
| 29 | Epitopes, T-Lymphocyte (immunology) |
| 29 | Computational Biology (methods) |
| 29 | Carboxypeptidases (metabolism) |
| 29 | CD4-Positive T-Lymphocytes (immunology) |
| 29 | Antiviral Agents (administration & dosage) |
| 28 | Viral Fusion Proteins (chemistry) |
| 28 | Reverse Transcriptase Inhibitors (chemistry) |
| 28 | Respiratory disease |
| 28 | Recombinant Proteins |
| 28 | RNA, Viral (blood) |
| 28 | Protease Inhibitors (chemical synthesis) |
| 28 | Phosphorylation |
| 28 | Models, Theoretical |
| 28 | Microscopy, Confocal |
| 28 | Membrane Glycoproteins (biosynthesis) |
| 28 | Genome |
| 28 | Endopeptidases (metabolism) |
| 28 | Coronavirus Infections (mortality) |
| 28 | Biological activity |
| 28 | Antiviral Agents (metabolism) |
| 28 | Antiviral Agents (isolation & purification) |
| 28 | Antibodies, Neutralizing (immunology) |
| 28 | Age Factors |
| 27 | Viral Structural Proteins (genetics) |
| 27 | Two-Hybrid System Techniques |
| 27 | RNA Interference |
| 27 | Pathogenesis |
| 27 | Open Reading Frames (genetics) |
| 27 | Infectious Disease Transmission, Patient-to-Professional |
| 27 | Hydrogen Bonding |
| 27 | Drug Discovery |
| 27 | Disease Progression |
| 27 | Coronavirus Infections (physiopathology) |
| 27 | Cohort Studies |
| 26 | Virus Internalization (drug effects) |
| 26 | Vaccines, Inactivated (immunology) |
| 26 | Transmissible gastroenteritis virus (genetics) |
| 26 | Reverse Transcriptase Inhibitors (chemical synthesis) |
| 26 | Receptors, Virus (chemistry) |
| 26 | Protease inhibitor |
| 26 | Peptides (metabolism) |
| 26 | Peptides (immunology) |
| 26 | Oligonucleotide Array Sequence Analysis |
| 26 | Middle East Respiratory Syndrome Coronavirus (isolation & purification) |
| 26 | Influenza A Virus, H5N1 Subtype |
| 26 | Health Knowledge, Attitudes, Practice |
| 26 | Green Fluorescent Proteins (metabolism) |
| 26 | Cross Infection (transmission) |
| 26 | Coronaviridae (genetics) |
